Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07150845 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A Phase 2 study of Atoptic Dermatitis, sponsored by Evommune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT07150845: Recruiting Phase 2 study of Atoptic Dermatitis, sponsored by Evommune.
NCT07150845 is a Phase 2 study of Atoptic Dermatitis that is actively recruiting participants, run by Evommune. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07150845, a Phase 2 study of Atoptic Dermatitis, is actively recruiting participants, sponsored by Evommune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG EVO756
- DRUG Placebo control
Study Locations (20)
Florida
- Skin Care Research, LLC - Boca Raton
- Driven Research, LLC - Coral Gables
- Skin Care Research - Hollywood Dermatology - Hollywood
- TrueBlue Clinical Research - Tampa
California
- Center for Dermatology Clinical Research - Fremont
- Metropolis Dermatology - Downtown Los Angeles - Los Angeles
- Skin and Beauty Center - Pasadena
New York
- Empire Dermatology - East Syracuse
- Equity Medical - New York
- Skin Search of Rochester, Inc. - Rochester
Michigan
- Great Lakes Research Group, Inc. - Bay City
- Revival Research Institute, LLC - Troy
Texas
- Stryde Research - Lewisville
- Progressive Clinical Research - San Antonio
Indiana
- DS Research - Clarksville
Kentucky
- Equity Medical - Bowling Green
Maryland
- Aesthetic and Dermatology Center - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT07150845 shows while recruiting
NCT07150845 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Atoptic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which EVO756 is the first listed.
NCT07150845 names 20 study sites across 11 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07150845 about?
NCT07150845 is a clinical study titled "Phase 2b Study of EVO756 in Adults With Atopic Dermatitis". This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
What is the current status of trial NCT07150845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-08-26. Estimated completion is 2026-07.
What conditions does trial NCT07150845 study?
This clinical trial studies the following conditions: Atoptic Dermatitis.
What interventions are being tested in trial NCT07150845?
The interventions under investigation include: EVO756 (DRUG), Placebo control (DRUG).
Who is sponsoring clinical trial NCT07150845?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07150845 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07150845's enrollment target sits among peer trials
120 569th of 2000 higher than 1,384 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI